Use of colony-stimulating factor primary prophylaxis and incidence of febrile neutropenia from 2010 to 2016: a longitudinal assessment

References

• Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24(19):3187–3205.
   PubMed Web of Science ®Google Scholar
• Caggiano V, Weiss RV, Rickert TS, et al. Incidence, cost and mortality of neutropenia hospitalization associated with chemotherapy. Cancer. 2005;103:1916–1924.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Michels SL, Reynolds MW, et al. Risk of mortality in patients with cancer who experience febrile neutropenia. Cancer. 2010;116:5555–5563.
   PubMed Web of Science ®Google Scholar
• Kuderer NM, Dale DC, Crawford J, et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006;106:2258–2266.
   PubMed Web of Science ®Google Scholar
• Bonadonna G, Moliterni A, Zambetti M, et al. 30 years’ follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. BMJ. 2005;330(7485):217.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Dale DC, Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol. 2003;21:4524–4531.
   PubMed Web of Science ®Google Scholar
• Kwak LW, Halpern J, Olshen RA, et al. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol. 1990;8(6):963–977.
   PubMed Web of Science ®Google Scholar
• NCCN. NCCN clinical practice guidelines in oncology (NCCN Guidelines): myeloid growth factors [v2.2016] [Internet] [cited 2017 Apr 7]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/myeloid_growth.pdf
   Google Scholar
• Pinto L, Liu Z, Doan Q, et al. Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials. Curr Med Res Opin. 2007;23(9):2283–2295.
   PubMed Web of Science ®Google Scholar
• Cooper KL, Madan J, Whyte S, et al. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer. 2011;11:404.
   PubMed Web of Science ®Google Scholar
• Wang L, Baser O, Kutikova L, et al. The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trials. Support Care Cancer. 2015;23(11):3131–3140.
   PubMed Web of Science ®Google Scholar
• Siena S, Piccart MJ, Holmes FA, et al. A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim per chemotherapy cycle and daily filgrastim in patients with stage II–IV breast cancer. Oncol Rep. 2003;10(3):715–724.
   PubMed Web of Science ®Google Scholar
• Hershman D, Hurley D, Wong M, et al. Impact of primary prophylaxis on febrile neutropenia within community practices in the US. J Med Econ. 2009;12(3):203–210.
   PubMedGoogle Scholar
• Lyman GH, Morrison VA, Dale DC, et al. Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin’s lymphoma receiving CHOP chemotherapy. Leuk Lymphoma. 2003;44:2069–2076.
   PubMed Web of Science ®Google Scholar
• Weycker D, Edelsberg J, Kartashov A, et al. Risk and healthcare costs of chemotherapy-induced neutropenic complications in women with metastatic breast cancer. Chemotherapy. 2012;58:8–18.
   PubMed Web of Science ®Google Scholar
• Weycker D, Li X, Tzivelekis S, et al. Burden of chemotherapy-induced febrile neutropenia hospitalizations in US clinical practice, by use and patterns of prophylaxis with colony-stimulating factor. Support Care Cancer. 2017;25(2):439–447.
   PubMed Web of Science ®Google Scholar
• Tan H, Tomic K, Hurley D, et al. Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study. Curr Med Res Opin. 2011;27:79–86.
   PubMed Web of Science ®Google Scholar
• Weycker D, Malin J, Barron R, et al. Comparative effectiveness of filgrastim, pegfilgrastim, and sargramostim as prophylaxis against hospitalization for neutropenic complications in patients with cancer receiving chemotherapy. Am J Clin Oncol. 2011;267–74.
   Web of Science ®Google Scholar
• Morrison VA, Wong M, Hershman D, et al. Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3–4 week chemotherapy regimens in community oncology practices. J Manag Care Pharm. 2007;13(4):337–348.
   PubMed Web of Science ®Google Scholar
• Weycker D, Li X, Barron R, et al. Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis in US clinical practice. Support Care Cancer. 2016;24(6):2481–2490.
   PubMed Web of Science ®Google Scholar
• Kuderer NM, Lyman GH. Personalized medicine and cancer supportive care: appropriate use of colony-stimulating factor support of chemotherapy. J Natl Cancer Inst. 2011;103(12):910–913.
   PubMedGoogle Scholar
• Smith TJ, Hillner BE. Bending the cost curve in cancer care. N Eng J Med. 2011;364(21):2060–2065.
   PubMed Web of Science ®Google Scholar
• Schnipper LE, Smith TJ, Raghavan D, et al. American society of clinical oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. J Clin Oncol. 2012;30(14):1715–1724.
   PubMed Web of Science ®Google Scholar
• Smith TJ, Hillner BE. A way forward on the medically appropriate use of white cell growth factors. J Clin Oncol. 2012;30(14):1584–1587.
   PubMed Web of Science ®Google Scholar
• Goyal RK, Tzivelekis S, Rothman KJ, et al. Time trends in utilization of G-CSF prophylaxis and risk of febrile neutropenia in a Medicare population receiving adjuvant chemotherapy for early-stage breast cancer. Support Care Cancer. 2018;26(2):539–548.
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services (2009) Code of Federal Regulations: Title 45, public welfare; Part 46, protection of human subjects [Internet] [cited 2013 Jul 4]. Available from: http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.html
   Google Scholar
• Weycker D, Sofrygin O, Seefeld K, et al. Technical evaluation of methods for identifying chemotherapy-induced febrile neutropenia in healthcare claims databases. BMC Health Serv Res. 2013;13:60.
   PubMed Web of Science ®Google Scholar
• Holmes FA, O’Shaughnessy JA, Vukelja S, et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol. 2002;20(3):727–731.
   PubMed Web of Science ®Google Scholar
• Green MD, Koelbl H, Baselga J, et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol. 2003;14(1):29–35.
   PubMed Web of Science ®Google Scholar
• Naeim A, Henk HJ, Becker L, et al. Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF). BMC Cancer. 2013;13:11.
   PubMed Web of Science ®Google Scholar
• Amgen Inc. Neulasta (pegfilgrastim) prescribing information. Thousand Oaks (CA): Amgen Inc.; 2009
   Google Scholar
• Weycker D, Bensink M, Lonshteyn A, et al. Risk of chemotherapy-induced febrile neutropenia by day of pegfilgrastim prophylaxis in US clinical practice from 2010–2015. Curr Med Res Opin. 2017;33(12):2107–2113.
   PubMed Web of Science ®Google Scholar
• Weycker D, Bensink M, Wu H, et al. Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis based on real-world data from 2010–2015. Curr Med Res Opin. 2017;33(12):2115–2120.
   PubMed Web of Science ®Google Scholar
• Weycker D, Li X, Figueredo J, et al. Risk of chemotherapy-induced febrile neutropenia in cancer patients receiving pegfilgrastim prophylaxis: does timing of administration matter? Support Care Cancer. 2016;24(5):2309–2316.
   PubMed Web of Science ®Google Scholar